Get started
Author

Rachel O. Abelman

Observed names: R. Abelman, R. O. Abelman, R.O. Abelman, Rachel Abelman, Rachel H. Occhiogrosso, Rachel H. Occhiogrosso Abelman, Rachel O Abelman, Rachel Occhiogrosso, Rachel Occhiogrosso Abelman
Observed institutions: Brigham and Women's Hospital, Harvard University, Brown University, Yale University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Women & Infants Hospital of Rhode Island, Mass General Brigham, American Society of Human Genetics
ORCID: 0000-0002-3946-7420
Observed ORCID: 0000-0002-3946-7420
OpenAlex ID: A5006042046
Mechanisms of Resistance to Antibody–Drug Conjugates
2023 · Rachel Occhiogrosso Abelman, Bogang Wu, et al. · Cancers · 154
PDF
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
2023 · L.M. Spring, S.M. Tolaney, et al. · Annals of Oncology · 86
TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer
2025 · Rachel O. Abelman, Bogang Wu, et al. · Clinical Cancer Research · 60
PDF
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
2023 · Rachel Occhiogrosso Abelman, Laura Spring, et al. · Journal of Clinical Oncology · 56
Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
2024 · Aditya Bardia, Sheng Sun, et al. · Clinical Cancer Research · 55
Bioinformatic Approach to the Genetics of Preeclampsia
2014 · Elizabeth W. Triche, Alper Uzun, et al. · Obstetrics and Gynecology · 41
Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker Analysis
2024 · Rachel Occhiogrosso Abelman, Laura Spring, et al. · Cancer Research · 24
The Hyde Amendment at 40 Years and Reproductive Rights in the United States
2017 · Eli Y. Adashi, Rachel H. Occhiogrosso Abelman · JAMA · 16
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.
2025 · Rachel Occhiogrosso Abelman, Shannon McLaughlin, et al. · Journal of Clinical Oncology · 15
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
2022 · Rachel Occhiogrosso Abelman, Arielle Medford, et al. · The Cancer Journal · 14
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
2024 · Rachel Occhiogrosso Abelman, Laura Spring, et al. · Journal of Clinical Oncology · 12
PDF
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis
2023 · Arielle J. Medford, Lauren Oshry, et al. · Therapeutic Advances in Medical Oncology · 12
PDF
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer
2026 · Bogang Wu, Win Thant, et al. · Journal for ImmunoTherapy of Cancer · 10
Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells
2026 · Avanish Mishra, Rachel O. Abelman, et al. · Proceedings of the National Academy of Sciences · 8
PDF
Feasibility of an Online Patient Community to Support Older Women With Newly Diagnosed Breast Cancer
2021 · Rachel H. Occhiogrosso, Siyang Ren, et al. · Clinical Breast Cancer · 8
Current and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast Cancer
2022 · Rachel Occhiogrosso Abelman, Jennifer C. Keenan, et al. · Hematology/Oncology Clinics of North America · 4
Thrombosis-Related Loss of Arterial Lines in the First Wave of COVID-19 and Non–COVID-19 Intensive Care Unit Patients
2022 · Rebecca L. Zon, Lauren E. Merz, et al. · Anesthesia & Analgesia · 4
Acute hypocalcemia following kidney transplantation may depend on the type of remote parathyroidectomy: a retrospective cohort study
2017 · Malorie Simons, Josef Bautista, et al. · Clinical Nephrology · 3
Nectin-4 expression in primary breast cancer and associated clinical outcomes.
2024 · Arielle J Medford, Andrzej Niemierko, et al. · Journal of Clinical Oncology · 2
Abstract 3888: TOP1 mutations mediate cross resistance to ADCs in metastatic breast cancer
2024 · Rachel Occhiogrosso Abelman, Haley Barnes, et al. · Cancer Research · 2
Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC
2024 · Laura M. Spring, Bogang Wu, et al. · Cancer Research · 2
826 A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer
2024 · Bogang Wu, Win Thant, et al. · Regular and Young Investigator Award Abstracts · 1
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
2024 · Aditya Bardia, Sheng Sun, et al. · 1
Abstract PO3-05-14: Practice patterns for sequential use of antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer: results from a physician survey
2024 · Yara Abdou, Prarthna Bhardwaj, et al. · Cancer Research · 1
Abstract PO3-13-09: Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: temporal dynamics and impact on clinical outcomes
2024 · Arielle Medford, Elyssa Denault, et al. · Cancer Research · 1
Works count: 70
Citation count: 595
H-index: 12
I10-index: 13
Year
Topic
Type